Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07100210 | A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity | recruiting | Phase 1 | 6 | Xingchen PengOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT07165067 | A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 36 | AP Biosciences Inc.INDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT07265622 |
| First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors |
| recruiting |
| Phase 1 / Phase 2 |
| 200 |
| Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY |
| 1 |
| Dec 29, 2025 |
| clinicaltrials |
| NCT06022029 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.(ON-5001) | recruiting | Phase 1 | 168 | OncoNano Medicine, Inc.INDUSTRY | 2 | Dec 24, 2025 | clinicaltrials |
| NCT07197827 | A Study of YL242 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 424 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 3 | Dec 24, 2025 | clinicaltrials |
| NCT07230977 | GenSci139 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 280 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07251166 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of GenSci140 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 170 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 24, 2025 | clinicaltrials |
| NCT05306132 | Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067 | recruiting | Phase 1 | 150 | Jiangsu Aosaikang Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06459973 | A Clinical Study of YL205 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 252 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 2 | Dec 23, 2025 | clinicaltrials |
| NCT06712680 | A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes | recruiting | Phase 1 / Phase 2 | 115 | Sichuan Huiyu Pharmaceutical Co., LtdINDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07292402 | JSKN022 in Subjects With Advanced Malignant Solid Tumors | recruiting | Phase 1 | 225 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07229586 | A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 19, 2025 | clinicaltrials |
| NCT06727812 | Multicenter Phase I Study of HRS-6208 in Patients With Solid Tumors | recruiting | Phase 1 | 206 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06825494 | Clinical Studies for the Treatment of Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 194 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07275073 | JMT106 Injection in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 200 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05856981 | Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | recruiting | Phase 1 | 130 | Sairopa B.V.INDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT07266285 | BTM-3566 in Advanced Solid Tumors | recruiting | Phase 1 | 30 | Bantam PharmaceuticalsINDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07288957 | A Early Study of ABSK131 in Patients With Advanced/Metastatic Solid Tumors(ABSK131-101) | recruiting | Phase 1 | 266 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06108050 | JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 177 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07285395 | AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study | recruiting | Phase 1 | 12 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07281326 | A Study of AK138D1 in Advanced Malignant Tumors | recruiting | Phase 1 | 200 | AkesoINDUSTRY | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06375187 | A Study of GC203 TIL in Advanced Malignant Solid Tumors(KUNLUN-001) | recruiting | Phase 1 | 18 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07274085 | A Phase 1 Study of HDM2017 in Advanced Solid Tumors | recruiting | Phase 1 | 96 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
| NCT05338658 | Study of PAT in Patients With Solid Tumor Cancers | recruiting | Phase 1 | 21 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT06241456 | FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors | recruiting | Phase 1 | 351 | Fate TherapeuticsINDUSTRY | 1 | Dec 9, 2025 | clinicaltrials |
| NCT06735144 | Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 5, 2025 | clinicaltrials |
| NCT07265921 | A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors(Solid Tumors) | recruiting | Phase 1 | 232 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06299839 | PAS-004 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 48 | Pasithea Therapeutics Corp.INDUSTRY | 3 | Dec 3, 2025 | clinicaltrials |
| NCT06703177 | A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors | recruiting | Phase 1 / Phase 2 | 876 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06925581 | A Trial of HRS-6768 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 84 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07021898 | A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.(BOREALIS-1) | recruiting | Phase 1 | 200 | Erasca, Inc.INDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07260591 | VSV-02 Compassionate Use in Advanced Solid Tumors | recruiting | Phase 1 | 6 | The First Affiliated Hospital of Xinxiang Medical CollegeOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06840821 | Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors | recruiting | Phase 1 / Phase 2 | 156 | Mainline Biosciences (Shanghai) Co., LtdOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07259889 | Safety and Tolerability Evaluation of CEL001 Injection in Advanced Solid Tumors | recruiting | Phase 1 | 13 | Guangzhou Xiling Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06439888 | Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer(LySATRA) | recruiting | Phase 1 / Phase 2 | 58 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07208136 | A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors | recruiting | Phase 1 | 102 | JemincareINDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07256782 | A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 444 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07241936 | A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 444 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07105215 | A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors | recruiting | Phase 1 / Phase 2 | 312 | RemeGen Co., Ltd.INDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT05547321 | Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors. | recruiting | Phase 1 | 150 | Oncomatryx Biopharma S.L.INDUSTRY | 2 | Nov 25, 2025 | clinicaltrials |
| NCT06478251 | T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor | recruiting | Phase 1 | 9 | TingBo LiangOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT06484790 | T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor | recruiting | Phase 1 | 9 | Ting DengOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07083323 | A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 262 | Sichuan Huiyu Pharmaceutical Co., LtdINDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT06238401 | An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 77 | Hangzhou Adcoris Biopharmacy Co., LtdINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07232420 | A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors | recruiting | Phase 1 | 33 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05914116 | A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 862 | DualityBio Inc.INDUSTRY | 4 | Nov 21, 2025 | clinicaltrials |
| NCT04299191 | Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 28 | Laminar PharmaceuticalsINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT05522868 | SB17170 Phase 1 Clinical Trial in Solid Tumors | recruiting | Phase 1 | 50 | SPARK BiopharmaINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06184035 | A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer(Tumorad) | recruiting | Phase 1 / Phase 2 | 90 | Spago Nanomedical ABINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06500676 | A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations | recruiting | Phase 1 / Phase 2 | 407 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 29, 2025source: clinicaltrials